BOSTON--(BUSINESS WIRE)--NMT Medical, Inc. (Nasdaq: NMTI) announced today that it has initiated the commercial launch of the Company’s bioabsorbable implant, BioSTAR®, in Europe and Canada. The unique, biomaterial, drug and device combination, which received the CE Mark in Europe and an HPB (Health Products and Food Branch) medical device license in Canada in June, has recently been implanted in several patients in both regions.
